Overview
JXR (1951)
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides...
- Open
- 2.280
- High
- 2.375
- Low
- 2.280
- Prev. Close
- 2.295
- Volume
- 18.75M
- Turnover
- 43.75M
- Avg Price
- 2.334
- Bid/Ask Ratio
- -93.14%
- Amplitude
- 4.14%
- 52wk High
- 2.628
- Volume Ratio
- 0.95
- Turnover Ratio
- 0.72%
- 52wk Low
- 1.920
- HK Mkt Cap
- 6.12B
- Market CapHKD
- 6.12B
- P/ETTM
- 31.05
- P/EDynamic
- 24.75
- P/EStatic
- --
- EPSTTM
- 0.0752
- EPSDynamic
- 0.0944
- EPSStatic
- --
- BVPS
- 3.91
- P/B
- 0.60
- HK Shares
- 2.62B
- Dividend YieldTTM
- 1.85%
- DividendTTM
- 0.043
- Shares
- 2.62B
- Min lot size
- 500
- Currency
- HKD
JXR Analyst Rating
View moreForecast & Rating
Oct 23, 2026- Strong buy64.29%
- Buy14.29%
- Hold7.14%
- Sell14.29%
- Strong sell0.00%
- Strong buy
- 9
- Buy
- 2
- Hold
- 1
- Sell
- 2
- Strong sell
- 0
Daily Events
- Nov, 16
Jinxin Fertility rose 1.91% to HK$2.335 on November 16, extending gains from a 3% surge on November 15, though with tempered momentum. Intraday showed divergence: the stock climbed to HK$2.375 in the morning session but retreated in afternoon trading, signaling profit-taking following the sharp rally. The company continues to drive shareholder returns, with recent share buyback announcements and a 2026-2028 return plan announced in September that targets increased dividends and buybacks. In September, Jinxin also launched a RMB1.93 billion asset securitization to provide liquidity for capital allocation. Fundamentally, Q2 earnings showed robust growth with EPS up 110.81% YoY, operating profit surging 131.05% YoY, and revenue reaching HK$793 million, demonstrating strong operational improvement. Valuation-wise, the stock trades at a PE of 31x, elevated relative to peers, while the PB of 0.60 is attractive. At a price 12.55% below the 52-week high of HK$2.67 and up 21.61% from the 52-week low, the stock remains in mid-range territory year-to-date, down 2.71% since January.
- Nov, 13
Jinxin Fertility (1951.HK) declined 1.96% to close at HKD 2.295, pressured by profit-taking after a period of strength, with morning session holding firm and peaking at HKD 2.350 at 10:35, but deteriorating in the afternoon to a low of HKD 2.285 at 15:52 before a modest recovery; turnover rate stood at 0.410%. On the earnings front, Q2 revenue reached HKD 793 million with 12.34% YoY growth, while net profit of HKD 62 million surged 110.88% YoY, and operating profit jumped 131.05% YoY, demonstrating significantly improved profitability; however, the current P/E of 30.5 remains elevated, with market pricing in high growth expectations. Positionally, the stock has declined 4.37% year-to-date and trades roughly 19.5% above its 52-week low of HKD 1.92, with the current price above the 20-day moving average at HKD 2.271. The company's recent buyback announcements and elevated 2026-2028 dividend targets reflect management confidence in long-term value, though these tailwinds have progressively faded into pricing.
- Nov, 12
The stock surged 2.4% to close at HKD 2.34 today, primarily driven by continued share buyback announcements and robust financial performance in recent quarters. The company has been consistently disclosing buyback transactions on the HKEX and has established elevated dividend and share repurchase targets for the 2026-2028 period, reflecting management's confidence in intrinsic value. Recent quarterly results demonstrate impressive earnings momentum: Q2 delivered EPS of HKD 0.0231, surging 110.81% year-over-year, with revenue reaching HKD 793 million, up 12.34% YoY; Q1 showed similar strength with EPS of HKD 0.0227, up 110.88% YoY, and net profit climbing over 110%, signaling notably enhanced profitability and operational efficiency. Market enthusiasm surrounding supportive healthcare policies for the reproductive medicine sector has also provided tailwinds for the stock, with a majority of brokers maintaining 'buy' ratings on the company. On the flip side, the stock still trades about 12% below its 52-week peak of HKD 2.67, and with a forward PE valuation of 31.15x, market participants should closely monitor whether the company can sustain this elevated earnings growth trajectory going forward.
- Nov, 11
Jinxin Fertility declined 1.5% to HKD 2.285, reflecting profit-taking pressures following a prior advance. The company has rolled out a more aggressive share buyback and dividend program for 2026–2028, with multiple repurchase disclosures filed recently, supported by favorable reproductive healthcare policy tailwinds. Q2 earnings underscore strong profit dynamics: revenue reached HKD 793.1 million, up 12.3% year-over-year, while net profit doubled to HKD 62.0 million (+110.88% YoY) and operating income surged 131% to HKD 113.4 million; EPS climbed 110.81% to 0.0231 HKD, sustaining a 7.82% net margin. Year-to-date performance stands at –4.79%, with the stock down 14.4% from its 52-week peak of HKD 2.67 (set January 18), though it remains above the 20-day moving average of 2.264 and well above the 60-day line. However, the ROE of 2.41% signals relatively modest capital returns, which warrants monitoring given the current 30.4x PE multiple and the need for earnings growth to justify valuation.
- Nov, 10
Jinxin Fertility advanced 0.65% to HKD 2.32, driven by ongoing share buyback programs and robust earnings growth. Q2 2026 EPS reached HKD 0.0231 with year-over-year growth of 110.81%, while revenue of HKD 793.1 million grew 12.34% YoY and net profit surged over 110%. Morning trading peaked at HKD 2.33 before retreating, with afternoon consolidating in the HKD 2.30-2.32 range on 6.52 million shares traded. Current price is down 3.33% from year-start but trades above the 20-day moving average at HKD 2.264, and the pullback from the 52-week high of HKD 2.67 stands at only 13.11%, indicating solid technical support. Management continues backing the stock through frequent share repurchases and a 2026-2028 enhanced dividend plan. The PE multiple of 30.93 remains elevated, and sustaining triple-digit profit growth rates will be key to justifying current valuations.
News
PUBT · Jinxin Fertility Files Next Day Disclosure Return With HKEX on Share Buyback
Market Movers · JXR climbs 3% in Hong Kong trading
PUBT · Jinxin Fertility Files Next Day Disclosure Return to HKEX Announcing Share Buyback
PUBT · Jinxin Fertility Discloses Share Buyback in HKEX Filing
PUBT · Jinxin Fertility Discloses Share Buyback in HKEX Next-Day Return
PUBT · Jinxin Fertility Files HKEX Next-Day Disclosure Return Announcing Share Buyback
